drugset / Trial / NCT01249651

To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

NCT01249651

Phase 4 Completed 101 enrolled AstraZeneca Quintiles, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg

Indications